MyFinsight
Home
Blog
About
Contact
Maturities of marketable
securities
$52,549K
Issuance of common stock
under equity-based...
$380K
Net cash provided by
(used in) investing...
$32,414K
Net cash provided by
financing activities
$380K
Canceled cashflow
$20,135K
Net increase in cash
and cash...
-$13,251K
Canceled cashflow
$32,794K
Equity-based compensation
expense
$7,616K
Accounts payable
$1,667K
Depreciation and
amortization
$79K
Purchase of marketable
securities
$20,135K
Net cash used in
operating activities
-$46,045K
Canceled cashflow
$9,362K
Net loss
-$49,661K
Accrued expenses and
other liabilities
-$4,307K
Accretion on marketable
securities
-$777K
Prepaid expenses and
other assets
$662K
Back
Back
Cash Flow
Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. (CGEM)
source: myfinsight.com